Insider Trading (Form 4)
NASDAQ
Chemomab Therapeutics CEO Adi Mor George reports transactions involving American Depositary Shares and Restricted Share Units.
Schedule 13D - Activist Investments
NASDAQ
Chemomab Therapeutics Ltd. shareholders, including HBM Healthcare Investments, have entered into a support agreement to vote in favor of the proposed merger with Scipher Medicine Corporation.
NASDAQ
OrbiMed Israel BioFund GP Limited Partnership and its affiliates have filed an exit Schedule 13D/A, reporting a reduction in their beneficial ownership of Chemomab Therapeutics Ltd. to below 5% following a sale of 1.61 million ADSs.
Capital raise
Worse than expected
Schedule 13G - Passive Investments
See all →NASDAQ
Touchstone Global Investments Pty Ltd has increased its beneficial ownership of Chemomab Therapeutics Ltd. American Depositary Shares to 5.2%.
NASDAQ
Erik Otto has filed a Schedule 13G, reporting beneficial ownership of 90,000 American Depository Shares in Chemomab Therapeutics Ltd., representing 1.2% of the class.
NASDAQ
Erik Otto has reported a 6.3% beneficial ownership stake in Chemomab Therapeutics Ltd., holding 385,000 American Depository Shares.
NASDAQ
SCHEDULE: Erik Otto Boosts Chemomab Stake to 8.1%
Erik Otto has increased his beneficial ownership in Chemomab Therapeutics Ltd. to 8.1% of the outstanding American Depository Shares.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported ceasing to be beneficial owners of more than five percent of Chemomab Therapeutics Ltd.'s ordinary shares.
NASDAQ
Morgan Stanley and its subsidiary have disclosed an 8.4% beneficial ownership stake in Chemomab Therapeutics Ltd. as of June 30, 2025.